| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-101 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第五次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交 ...

Financial Performance - In Q3 2024, the company achieved operating revenue of 606.11 million yuan, a year-on-year increase of 17.51% [1] - Net profit attributable to shareholders reached 80.14 million yuan, up 22.70% from the previous year [1] - Net profit excluding non-recurring gains and losses was 62.70 million yuan, reflecting a significant growth of 49.89% year-on-year [1] Business Segments - The international department maintained stable qualitative business while experiencing rapid growth in quantitative business, particularly in overseas fluorescence platforms [1] - The U.S. subsidiary's toxicology business remained stable, with significant growth expected in respiratory infectious disease testing, including new COVID-19 and flu combination tests [2] - Domestic operations are divided into qualitative and quantitative segments, with qualitative business showing rapid growth in infectious disease testing [2] Market Expansion - The company is actively expanding sales channels, focusing on offline pharmacies, supermarkets, and online platforms like Amazon [2] - Localized factories are being established in various countries to mitigate potential policy risks and enhance market opportunities [3] - The company has successfully registered respiratory combination tests in several countries, anticipating future business opportunities [4] Cost and Profitability - Sales and management expenses increased in Q3 due to the recognition of stock incentive costs, but overall expense ratios have decreased compared to the previous year [3] - Gross margin showed a slight improvement due to product structure optimization and increased sales of higher-margin products [4] Future Outlook - The international department is expected to continue strong performance, with significant growth anticipated in the fourth quarter driven by respiratory disease products [4] - The company remains confident in achieving its annual revenue and profit targets despite external challenges [4]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-100 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第四次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当期转股价 48.56 元/股 的 70%，即 33.99 元/股；2024 年 9 月 11 日至 2024 年 10 月 22 日连续二十三个 交易日的收盘价格低于当期转股价 48.58 元/股（因部分限制性股票回购注销导致 公 ...

Investment Rating - The report maintains a "Recommended" rating for the company [2][4]. Core Views - The company's performance in Q3 2024 met expectations, with a revenue of 2.181 billion yuan (+8.83%) and a net profit of 436 million yuan (+9.04%) for the first nine months of 2024. The Q3 revenue was 606 million yuan (+17.51%) and net profit was 80 million yuan (+22.70%) [2]. - The company demonstrated resilience in a challenging domestic market, with growth driven by a gradual recovery in hospital admissions and successful overseas product registrations [2][4]. - The gross margin for Q3 2024 was 61.07%, slightly up by 0.3 percentage points year-on-year, benefiting from an optimized product mix. The company also achieved a significant reduction in operating expense ratios, indicating improved operational efficiency [2][4]. - Recent advancements in overseas product certifications are expected to support rapid growth in international business, including malaria detection products and FDA approvals for fentanyl and COVID-19 testing kits [2][4]. Financial Forecasts - The company is projected to achieve revenues of 3.0905 billion yuan in 2024, with a growth rate of 11.78%. Net profit is expected to reach 655.46 million yuan, reflecting a growth rate of 34.42% [5]. - For the years 2025 and 2026, revenues are forecasted at 3.71212 billion yuan and 4.40689 billion yuan, with respective growth rates of 20.11% and 18.72%. Net profits are expected to be 811.60 million yuan and 982.11 million yuan, with growth rates of 23.82% and 21.01% [5][9].

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2024-099 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债回售的第三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当 ...

Financial Performance - Revenue for the third quarter reached 606.11 million yuan, a year-on-year increase of 17.51%[2] - Net profit attributable to shareholders of the listed company was 80.14 million yuan, up 22.70% year-on-year[2] - Operating cash flow for the first three quarters was 173.32 million yuan, a significant increase of 577.95% year-on-year[2] - Total operating income reached 2,181,361,474.64 RMB, compared to 2,004,422,655.85 RMB in the same period last year[14] - Net profit attributable to the parent company's owners rose to 3,420,009,443.28 RMB, up from 3,171,439,111.97 RMB[13] - Net profit attributable to parent company shareholders reached 435.94 million yuan, a year-on-year increase of 9.04%[15] - Operating profit increased to 498.11 million yuan, up 7.64% compared to the same period last year[15] - Basic earnings per share (EPS) stood at 0.94 yuan, a 3.30% increase from the previous year[16] - Total comprehensive income amounted to 439.59 million yuan, reflecting a 9.93% year-on-year growth[16] - Sales revenue from goods and services reached 1.87 billion yuan, a 2.69% increase compared to the same period last year[17] Assets and Liabilities - Total assets as of the end of the reporting period were 6.75 billion yuan, an increase of 16.95% compared to the end of the previous year[2] - Total assets increased to 6,750,053,993.88 RMB, up from 5,771,717,185.26 RMB in the previous period[12][13] - Total liabilities stood at 1,183,419,313.40 RMB, slightly higher than 1,157,093,084.26 RMB in the previous period[13] - Fixed assets increased to 1,282,158,369.63 RMB, up from 1,016,780,459.03 RMB[12] - Long-term equity investments grew to 443,241,958.45 RMB, compared to 406,358,589.06 RMB[12] - Total equity attributable to the parent company's owners rose to 5,470,222,938.09 RMB, up from 4,515,967,763.10 RMB[13] - The company's monetary funds decreased by 68.56%, mainly due to increased investment in financial products[5] - The company's monetary funds decreased from 840,297,176.03 yuan at the beginning of the period to 264,158,244.73 yuan at the end of the period[11] - The company's trading financial assets increased from 722,446,137.96 yuan at the beginning of the period to 1,850,756,466.78 yuan at the end of the period[11] - The company's accounts receivable increased from 598,217,984.70 yuan at the beginning of the period to 884,077,440.58 yuan at the end of the period[11] - The company's inventory increased from 351,400,529.24 yuan at the beginning of the period to 390,925,976.28 yuan at the end of the period[11] - The company's other current assets decreased from 650,344,551.61 yuan at the beginning of the period to 274,961,521.60 yuan at the end of the period[11] Expenses and Costs - The company's financial expenses increased by 227.46% year-on-year, mainly due to exchange rate fluctuations[5] - Operating costs amounted to 1,715,728,355.95 RMB, up from 1,615,373,174.63 RMB in the previous year[14] - R&D expenses increased to 271,181,881.59 RMB, compared to 259,473,251.75 RMB in the prior year[14] - Sales expenses increased to 472,005,966.72 RMB, compared to 465,933,408.93 RMB in the previous year[14] - Interest expenses rose slightly to 21.63 million yuan, a 0.66% increase from the previous year[15] Investment and Income - Investment income decreased by 92.58% year-on-year, primarily due to smaller scale of matured financial products compared to the same period last year[5] - Fair value change income increased by 71.62% year-on-year, driven by unrealized gains from financial products[5] - Credit impairment losses surged by 1943.83% year-on-year, mainly due to increased bad debt provisions for receivables[5] - Investment income decreased significantly to 1.96 million yuan, down 92.58% year-on-year[15] - Cash inflow from investment activities totaled RMB 2.95 billion, up from RMB 2.43 billion in the prior year[18] - Cash outflow from investment activities increased to RMB 4.35 billion from RMB 2.42 billion in the same period last year[18] - Cash paid for investments surged to RMB 4.05 billion from RMB 2.12 billion in the same period last year[18] Shareholders and Equity - The total number of ordinary shareholders at the end of the reporting period is 40,991[6] - Li Wenmei, the largest shareholder, holds 20.32% of the company's shares, totaling 97,843,968 shares[6] - Wang Jihua, the second-largest shareholder, holds 10.30% of the company's shares, totaling 49,594,740 shares[6] - Guangzhou Huiyin Tianyue Equity Investment Fund Management Co., Ltd., a state-owned legal entity, holds 10.22% of the company's shares, totaling 49,195,579 shares[6] - The company's restricted shares increased by 37,371,992 shares during the reporting period, reaching a total of 111,183,968 shares[10] - The company's capital reserve increased by 92.43%, primarily due to capital premium from the private placement[5] Cash Flow - Cash flow from operating activities totaled 1.95 billion yuan, slightly higher than the previous year's 1.94 billion yuan[17] - Operating cash flow net amount for the quarter was RMB 173.32 million, compared to a negative RMB 36.26 million in the same period last year[18] - Total cash outflow from operating activities was RMB 1.78 billion, a decrease from RMB 1.98 billion in the previous year[18] - Net cash flow from financing activities was RMB 644.78 million, a significant improvement from a negative RMB 418.97 million in the previous year[18] - Cash and cash equivalents at the end of the period stood at RMB 263.58 million, down from RMB 732.32 million at the beginning of the period[18] - The company received RMB 864.08 million from capital absorption, a substantial increase from RMB 45.85 million in the same period last year[18] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was RMB 292.38 million, slightly lower than RMB 293.99 million in the previous year[18] - The company's cash and cash equivalents decreased by RMB 576.00 million during the quarter, compared to a decrease of RMB 428.11 million in the same period last year[18] Other Comprehensive Income - Other comprehensive income showed a negative value of -222,870.57 yuan, compared to a positive 2.22 million yuan in the same period last year[16] - Foreign exchange translation differences contributed -84,915.68 yuan to other comprehensive income[16]

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2024-097 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债回售的第二次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 6、投资者回售款到账日：2024 年 11 月 7 日 7、回售期申报期内万孚转债暂停转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当期转股价 48.56 元/股 的 70%，即 33.99 元/股；2024 年 9 月 11 日至 2024 年 10 月 22 日连续二十三个 交易日的收盘价格低于当期转股价 48.58 元/股（因部分限制性股票回购注销导致 公司股本减少， ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-096 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 6、投资者回售款到账日：2024 年 11 月 7 日 现将"万孚转债"回售有关事项公告如下： 一、回售情况概述 1、回售条款 根据《募集说明书》，有条件回售条款的约定如下： 本次发行的可转债最后两个计息年度，如果公司股票在任意连续三十个交易 日的收盘价格低于当期转股价格的 70%时，可转债持有人有权将其持有的可转 债全部或部分按债券面值加上当期应计利息的价 ...

Core Viewpoint - The Guangzhou Municipal Bureau of Industry and Information Technology has released the first batch of the "Guangzhou Innovative Drug and Medical Device Product Catalog," which aims to significantly reduce the medication burden on patients by covering major disease areas such as tumors, immunity, and cardiovascular diseases [1] Company Summary - Wanfu Biological's thrombus early screening project, which is the first in China to receive certification for market launch, has had its four testing reagents (TAT/PIC/TM/t-PAIC) included in the catalog, supporting early diagnosis and treatment of thrombus and hemostatic diseases [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2024-094 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债回售的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.266 元人民币/张（含息、税） 2、回售条件触发日：2024 年 10 月 22 日 3、回售申报期：2024 年 10 月 25 日至 2024 年 10 月 31 日 4、发行人资金到账日：2024 年 11 月 5 日 5、回售款划拨日：2024 年 11 月 6 日 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 广州万孚生物技术股份有限公司（以下简称"公司"）的股票自 2024 年 9 月 1 日至 2024 年 9 月 10 日连续七个交易日的收盘价格低于当期转股价 48.56 元/股 的 70%，即 33.99 元/股；2024 年 9 月 11 日至 2024 ...